Loading
Nuclear medicine physician who led the trials that got PSMA PET approved in the United States.
Thomas Hope is Professor of Radiology and Chief of Nuclear Medicine at UCSF, within the UCSF Helen Diller Family Comprehensive Cancer Center. A nuclear medicine physician specialising in PSMA PET and theranostics, his prospective studies of 68Ga-PSMA-11 PET at UCSF and UCLA supported the first FDA approval of PSMA PET in the United States in 2020. His papers include a JAMA Oncology multicentre prospective phase 3 imaging trial of the diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis before radical prostatectomy and a JAMA Oncology prospective single-arm trial assessing its accuracy in localising recurrent prostate cancer. He leads theranostics research and PSMA radioligand dosimetry work in prostate cancer.
Shares PET (positron emission tomography), PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial, PSMA-PreRP, UCSF Helen Diller Family Comprehensive Cancer Center, PSMA.
Shares UCSF Helen Diller Family Comprehensive Cancer Center, PSMA, PSMA PET, Radioligand therapy (beta emitters).
Shares PET (positron emission tomography), PSMA, Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial, PSMA-PreRP, PSMA, PSMA PET.
Shares PSMA, PSMA PET, Radioligand therapy (beta emitters), Prostate cancer.